Status:

COMPLETED

Use of a Bimodal Solution for Peritoneal Dialysis

Lead Sponsor:

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Collaborating Sponsors:

Baxter Healthcare Corporation

Conditions:

End Stage Renal Disease

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

Peritoneal dialysis (PD) is the method of renal replacement therapy used by close to 200,000 end stage renal disease patients worldwide to help replace the functions that are no longer performed by th...

Eligibility Criteria

Inclusion

  • Be able to provide informed consent
  • Age greater than 18 years
  • Be stable Automated Peritoneal Dialysis (APD) patients for at least 6 weeks
  • Be APD patients who;
  • Can be managed with an icodextrin long dwell AND
  • Will use 4.25% and/or a 2.5% solution for at least one exchange overnight in at least 5 out of 7 days
  • Have residual urine volume \<800 ml/24 hours
  • Long dwell must be or patient must tolerate at least an 8-10 hr long dwell.

Exclusion

  • Scheduled Transplant in the next 1 year
  • Life expectancy \< 3 mo (estimated by physician)
  • Participating in other trial that could influence outcome of this trial
  • Known icodextrin allergy
  • Currently using non-Baxter PD solutions
  • Systolic blood pressure \< 90 mm Hg on more than three occasions during a seven day period, despite discontinuation of non-essential anti-hypertensives
  • Supplementary Exclusion Criteria (post Run-in phase):
  • 1\) Unsuccessfully completed 1 week run-in phase. Defined as:
  • Not using bimodal solution on 7 consecutive days during the run-in
  • Not tolerating the increased UF anticipated with the bimodal solution. Tolerating defined as:
  • i) Blood pressure drop below 90/50 on more than three occasions during a seven day period that cannot be corrected by reducing anti-hypertensives or other simple measures ii) Intolerable feeling of fullness with the bimodal solution iii) Allergic reaction (although all patients have already been exposed to icodextrin)

Key Trial Info

Start Date :

September 30 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 28 2015

Estimated Enrollment :

36 Patients enrolled

Trial Details

Trial ID

NCT01242904

Start Date

September 30 2010

End Date

February 28 2015

Last Update

August 28 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

London Health Sciences Centre, South Street Hospital, Peritoneal Dialysis Unit

London, Ontario, Canada, N6A 5W9